SARS-CoV-2 N (BN18) Monoclonal
To Order Contact us: stephen@expresspharmapulse.com
SARS CoV-2 RT PCR kit |
|||
RTq-H731-50R | Bioingentech | 50T | EUR 1155.6 |
Mouse Monoclonal Anti-SARS Spike IgG |
|||
AB-17910 | Alpha Diagnostics | 50 ug | EUR 562.8 |
Mouse Anti-Human CTLA-4 (CD152) Monoclonal antibody, clone BN13 |
|||
CABT-L4463-1mg | Creative Diagnostics | 1 mg | EUR 1076.4 |
Mouse Anti-Human CTLA-4 (CD152) Monoclonal antibody, clone BN13 |
|||
CABT-L4463-5mg | Creative Diagnostics | 5 mg | EUR 2886 |
SARS CoV E Protein |
|||
abx060650-1mg | Abbexa | 1 mg | EUR 2030.4 |
Mouse Monoclonal Anti-SARS Spike Protein IgG |
|||
AB-15710 | Alpha Diagnostics | 20 ug | EUR 489.6 |
SARS CoV-2 One-Step PCR kit |
|||
Oneq-H731-100R | Bioingentech | 100T | EUR 1932 |
SARS CoV-2 One-Step PCR kit |
|||
Oneq-H731-150R | Bioingentech | 150T | EUR 2646 |
SARS CoV-2 One-Step PCR kit |
|||
Oneq-H731-50R | Bioingentech | 50T | EUR 1410 |
Monoclonal SAR1A Antibody (monoclonal) (M01), Clone: 3G5 |
|||
AMM07710G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A Monoclonal antibody against Human SAR1A (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3G5. This antibody is applicable in WB |
SARS-CoV-2 N Recombinant Antibody |
|||
A73671 | EpiGentek |
|
|
SARS-CoV-2 N Recombinant Antibody |
|||
A73676 | EpiGentek |
|
|
3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate |
|||
79952-1 | BPS Bioscience | 1 mg | EUR 445 |
Description: Sensitive internally quenched fluorogenic (FRET) substrate for SARS main protease with a Km value of 17 µM and a kcat value of 1.9 s»¹. |
3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate |
|||
79952-2 | BPS Bioscience | 10 mg | EUR 3460 |
Description: Sensitive internally quenched fluorogenic (FRET) substrate for SARS main protease with a Km value of 17 µM and a kcat value of 1.9 s»¹. |
SARS CoV Nucleocapsid Protein |
|||
abx060652-1mg | Abbexa | 1 mg | EUR 2247.6 |
Mouse Monoclonal Anti-SARS Nucleocapsid protein IgG |
|||
AB-17810 | Alpha Diagnostics | 50 ug | EUR 562.8 |
Mouse Monoclonal Anti-SARS Nucleocapsid Protein IgG |
|||
AB-18010 | Alpha Diagnostics | 50 ug | EUR 562.8 |
Hexokinase-2( N-term) Monoclonal Antibody |
|||
27074-100ul | SAB | 100ul | EUR 302.4 |
Hexokinase-2( N-term) Monoclonal Antibody |
|||
27074-50ul | SAB | 50ul | EUR 224.4 |
Monoclonal SART2 Antibody (monoclonal) (M03), Clone: 6D4 |
|||
AMM04069G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A Monoclonal antibody against Human SART2 (monoclonal) (M03). The antibodies are raised in mouse and are from clone 6D4. This antibody is applicable in WB, E |
SARS-CoV-2 (COVID-19) Nucleocapsid (N) Recombinant Protein |
|||
10-080 | ProSci | 0.1 mg | EUR 619.8 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). In both SARS-CoV and SARS-CoV-2, the CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. The NTD of SARS-CoV-2 does not bind to ACE2 6, and the function of NTD in SARS-CoV-2 infection is not well understood. In other CoVs, the NTD may promote attachment by binding to sugar moieties 7 and might play a role in the conformational change of S2 required for membrane fusion 8. While most neutralizing antibodies target the RBD domain and block receptor binding, potent neutralizing antibodies targeting NTD were isolated from convalescent COVID19 patients 9, identifying the NTD as an attractive candidate for vaccines and therapeutics. In addition, the NTD is a promising antigen for diagnostic tests, as there is only 53.5% homology between the NTD of SARS-CoV-2 and SARS-CoV 10. |
SARS-CoV-2 (COVID-19) NSP7 Peptide |
|||
9155P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP7 Peptide |
SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
9159P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide |
SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
9161P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide |
SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
9163P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide |
SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
9167P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide |
SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
9171P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide |
SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
9173P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide |
SARS-CoV-2 (COVID-19) NSP4 Peptide |
|||
9175P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP4 Peptide |
SARS-CoV-2 (COVID-19) NSP6 Peptide |
|||
9177P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP6 Peptide |
SARS-CoV-2 (COVID-19) ORF6 Peptide |
|||
9189P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF6 Peptide |
SARS-CoV-2 (COVID-19) ORF8 Peptide |
|||
9287P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide |
SARS-CoV-2 (COVID-19) ORF8 Peptide |
|||
9289P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide |
SARS-CoV-2 (COVID-19) NSP7 Antibody |
|||
9155-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |
SARS-CoV-2 (COVID-19) NSP7 Antibody |
|||
9155-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |
SARS-CoV-2 (COVID-19) NSP8 Antibody |
|||
9159-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |